Polysulfone block copolymers as drug-eluting coating material

• US 8,017,142 B2
• Filed: 06/02/2009
• Issued: 09/13/2011
• Est. Priority Date: 11/25/2003
• Status: Expired due to Fees

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Claude, Charles D., Yu, Yeung Siu, Ding, Ni
• Primary Examiner(s): Yu; Gina C
• Assistant Examiner(s): Pallay; Michael B
• Application Number:
  US12/476,987
• Publication Number:
  US 20090238856A1
• Time in Patent Office: 833 Days
• Field of Search: 424/423, 424/422, 514/772.1, 514/772, 514/772.3
• US Class Current: 424/423
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 81/06 Polysulfones; Polyethersulfones

Abstract

A polymeric composition comprising a polysulfone polymer and an elastomeric polymer for use as a coating composition for coating an implantable device, such as a DES, and methods of making and using the implantable device are provided.

Claims

1. A method of forming an implantable device, comprising

forming a coating on the implantable device, the coating comprising a polymeric composition comprising a block copolymer comprising a polysulfone (A) and an elastomeric polymer (B), wherein the polysulfone and the elastomeric polymer form a conjugate by direct chemical bonding, and

wherein the elastomeric polymer is selected from the group consisting of polyisobutylene, polyperfluoroalkylene, polyhexafluoropentene, poly(butyl methacrylate), poly(lauryl methacrylate), polyalkylene oxide, polyalkylene oxide acrylate, and a combination thereof.

2. The method of claim 1, wherein the elastomeric polymer is selected from the group consisting of polyisobutylene, polyperfluoroalkylene, polyhexafluoropentene, poly(butyl methacrylate), poly(lauryl methacrylate), polyalkylene oxide acrylate, and a combination thereof.

3. The method of claim 1, wherein the block copolymer comprises at least one block of a polysulfone polymer (A) and at least one block of an elastomeric polymer (B) in a general formula selected from AB, ABA or BAB.

4. The method of claim 1 wherein the implantable device is a stent.

5. The method of claim 1, wherein the coating further comprises a bioactive agent.

6. The method of claim 5, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, sirolimus, sirolimus derivatives, paclitaxel, taxoids, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), and a combination thereof.

7. The method of claim 1, wherein the polysulfone and the elastomeric polymer form a conjugate comprising a block copolymer, wherein the block copolymer is selected from the group consisting of

8. The method of claim 7, wherein R₁ is butyl, isobutyl or isopropyl;

wherein R₂ is hydrogen or methyl;

wherein R₃ is hydrogen, halo, or methyl;

wherein R₄ and R₅ are independently hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, or phenyl;

wherein R₆ is CF₂CF₃, CF₂CF₂CF₃, perfluoroisopropyl, perfluorobutyl or perfluoroisobutyl; and

wherein R₇ and R₈ are independently methyl, ethyl, propyl, isopropyl, butyl, or isobutyl group.

9. The method of claim 7, wherein R₁ is butyl;

wherein R₂ is methyl;

wherein R₃ is hydrogen;

wherein R₄ or R₅ are methyl groups; and

wherein R₇ and R₈ are methyl groups.